Prolia (Denosumab) and Tadalafil Interaction: What Women Need to Know

Does Taking Prolia and Tadalafil Together Cause a Drug Interaction?

No clinically significant direct interaction between denosumab and tadalafil has been identified in current DDI databases or primary literature. Denosumab is a fully human monoclonal antibody that acts on RANK-L and is not processed through hepatic CYP450 pathways, so it cannot inhibit or induce the CYP3A4 enzyme that tadalafil depends on for clearance. The two drugs work through completely separate mechanisms and share no overlapping metabolic routes.

"no pharmacokinetic interaction" is not the same as "take both without a second thought." Tadalafil carries a vasodilatory pharmacodynamic profile that can become clinically relevant when stacked with other drugs that lower blood pressure, and many women taking Prolia for postmenopausal osteoporosis are also managing hypertension, cardiovascular disease, or other conditions that involve vasoactive medications.

Why the Question Arises

Tadalafil (Cialis, Adcirca, Alyq) is approved by the FDA for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension (PAH). In women, its use is almost exclusively for PAH. Women account for roughly 75 percent of PAH cases, making tadalafil a drug that women's-health clinicians encounter regularly, even though most interaction guides still present tadalafil in a male-default frame.

Prolia (denosumab 60 mg subcutaneous every 6 months) is the most widely prescribed injectable therapy for postmenopausal osteoporosis in the United States, and postmenopausal women represent the primary population in which it is studied. So the combination of denosumab plus tadalafil is a real clinical scenario, particularly in a postmenopausal woman with PAH and established osteoporosis.

What "No Direct Interaction" Actually Means for You

Your pharmacist's interaction checker may return a "no interaction found" result, which is accurate at the pharmacokinetic level. Still, your prescriber should review your full medication list because the real interaction risk involves the drugs around tadalafil, not tadalafil itself. Nitrates, alpha-blockers, antihypertensives, and certain antifungals are the agents that actually change how tadalafil behaves in your body.

Mechanism Deep Dive: Why These Two Drugs Don't Interfere

Understanding the mechanism helps you have a more specific conversation with your doctor than "my pharmacist said it was fine."

How Denosumab Works and Is Cleared

Denosumab is a fully human IgG2 monoclonal antibody that binds RANK-L (receptor activator of nuclear factor kappa-B ligand), blocking the signal that drives osteoclast formation and activity. Because it is a large-molecule biologic, it is cleared through reticuloendothelial system catabolism into amino acids, not through the hepatic CYP enzyme system. It has no meaningful effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. P-glycoprotein is also not involved. Renal clearance is negligible for a molecule of this size. This metabolic profile means denosumab simply has no pathway through which it could raise or lower tadalafil plasma concentrations.

How Tadalafil Works and Is Cleared

Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in smooth muscle cells. By raising cyclic GMP, tadalafil relaxes vascular smooth muscle, producing vasodilation. In pulmonary arterial hypertension, this reduces pulmonary vascular resistance. Tadalafil is metabolized primarily by CYP3A4 in the liver, with a half-life of approximately 17.5 hours. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) can double tadalafil AUC; strong inducers (rifampin) can reduce it by 88 percent. Denosumab does neither.

The Pharmacodynamic Overlap to Watch

Even though there is no PK interaction, PDE5 inhibitors produce systemic vasodilation that can add to the blood-pressure-lowering effect of any co-administered antihypertensive. The FDA tadalafil label specifically warns against combining tadalafil with nitrates in any form because of the risk of severe hypotension. If you take denosumab and tadalafil and you also take an ACE inhibitor, an ARB, a calcium channel blocker, or a nitrate for chest pain, the clinically relevant question is not "denosumab vs. Tadalafil" but "tadalafil plus my antihypertensive regimen."

Women-Specific Physiology: How Sex and Hormones Change the Picture

Most tadalafil pharmacokinetic studies were conducted primarily in men, which is a documented gap. Here is what the available data and physiological reasoning tell us about how being a woman affects this picture across life stages.

Postmenopausal Women: The Primary Denosumab Population

Postmenopausal estrogen loss is the central driver of bone resorption acceleration. Estrogen normally suppresses RANK-L expression; when estrogen falls, RANK-L rises, osteoclast activity increases, and bone mineral density drops by up to 20 percent in the first five years after menopause. Denosumab directly counteracts this mechanism by blocking RANK-L.

Postmenopausal women are also at higher cardiovascular risk than premenopausal women, and some require tadalafil for PAH. In this population, the interaction audit is really about blood pressure management: is your systolic blood pressure already on the lower end? Do you take a diuretic, an alpha-blocker for bladder symptoms, or a nitrate? Those are the combinations to flag with your doctor, not denosumab itself.

Estrogen loss also changes vascular tone. Postmenopausal women may be more sensitive to the hypotensive effects of PDE5 inhibitors than premenopausal women, though direct comparative clinical data in women are limited.

Perimenopausal Women

Perimenopause is not commonly the life stage in which denosumab is prescribed, but it can occur in women with premature ovarian insufficiency (POI) or secondary osteoporosis (from glucocorticoid use, eating disorders, or cancer treatment). If you are perimenopausal, still having irregular cycles, and prescribed tadalafil for PAH, the contraception question becomes critical. See the pregnancy section below.

Reproductive-Age Women With PCOS or Endometriosis

Neither PCOS nor endometriosis directly changes the denosumab-tadalafil pharmacological picture. But women with PCOS who develop osteoporosis early (which is uncommon but documented in lean PCOS phenotypes) or women with endometriosis who have undergone bilateral oophorectomy and sustained bone loss may find themselves on denosumab at a younger age than typical. In those cases, the concern about tadalafil-induced hypotension should factor in any hormonal therapies being used.

Prolia Drug Interactions: The Bigger Picture

Because the denosumab-tadalafil pairing itself carries low direct risk, it is worth zooming out to the interactions that actually matter with Prolia.

Calcium and Vitamin D: The Required Pairing

The FDA Prolia label states that all patients must receive adequate calcium and vitamin D supplementation during treatment. Denosumab suppresses osteoclast activity so effectively that without adequate calcium intake, serum calcium can fall, producing hypocalcemia. This risk is higher in women with:

• Renal impairment (GFR <30 mL/min)
• Malabsorption syndromes
• Hypoparathyroidism
• Recent parathyroid surgery

Typical supplementation in trials such as FREEDOM (the key phase 3 trial that established Prolia's fracture efficacy in postmenopausal women) was at least 1,000 mg calcium and 400 IU vitamin D daily.

Immunosuppressants and Infection Risk

Denosumab modestly suppresses immune function. The FREEDOM trial showed a small but statistically significant increase in serious skin infections (cellulitis) in the denosumab arm (0.3 percent vs. 0.1 percent placebo). Women on concurrent immunosuppressants (methotrexate, corticosteroids, biologics for rheumatoid arthritis or IBD) face additive infection risk that warrants monitoring.

Drugs That Affect Calcium Metabolism

Loop diuretics increase urinary calcium excretion and can worsen denosumab-associated hypocalcemia. If you take furosemide or bumetanide, your calcium levels need closer monitoring after each Prolia injection.

What About Tadalafil's Own Key Interactions?

For completeness, the drugs that genuinely interact with tadalafil are:

• Nitrates (absolute contraindication): Combined use risks severe, potentially fatal hypotension per the FDA label
• Strong CYP3A4 inhibitors: Ketoconazole, itraconazole, ritonavir raise tadalafil AUC significantly and may require dose reduction
• Strong CYP3A4 inducers: Rifampin, carbamazepine, phenytoin reduce tadalafil exposure and may reduce efficacy
• Alpha-blockers: Additive hypotension; the label recommends initiating alpha-blockers at the lowest dose and allowing hemodynamic stability before adding tadalafil
• Antihypertensives: Additive blood pressure lowering; the label documents mean additional blood pressure reductions of 8/7 mmHg when tadalafil 20 mg is combined with amlodipine

None of these involve denosumab.

Pregnancy, Lactation, and Contraception

This section is required for any drug article at WomanRx, and it carries particular weight here because both drugs have data gaps in women of reproductive age.

Denosumab in Pregnancy: Contraindicated

Denosumab is contraindicated in pregnancy. RANK-L signaling is essential for normal fetal lymph node development and bone formation. Animal studies using doses producing exposures five times the human clinical exposure showed fetal lymph node agenesis, bone abnormalities, and absent mammary gland development in offspring. Human case reports of denosumab exposure in pregnancy describe neonatal hypocalcemia and bone abnormalities, though the dataset is small.

The FDA label requires that females of reproductive potential use effective contraception during denosumab therapy and for at least five months after the last dose because of the long serum half-life (approximately 26 days) and prolonged pharmacodynamic effect on RANK-L suppression. If you are prescribed Prolia and you could become pregnant, contraception is not optional.

A pregnancy exposure registry exists (the PRISM registry) to collect outcomes data; if you were exposed to denosumab in pregnancy, your provider can enroll you.

Lactation

Whether denosumab is present in human breast milk is unknown. IgG antibodies are generally found in breast milk at low concentrations, and oral bioavailability of large proteins is minimal in infants, but formal pharmacokinetic studies in lactating women have not been performed. The FDA label states that the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need and potential infant risk. This is a decision to make with your prescribing clinician.

Tadalafil in Pregnancy and Lactation

Tadalafil is FDA Pregnancy Category B (animal studies show no harm; no adequate human studies). In the context of PAH, which carries significant maternal and fetal mortality risk if untreated, most PAH guidelines suggest continuing effective vasodilator therapy with careful monitoring rather than stopping it. The European Society of Cardiology recommends that women with PAH avoid pregnancy, but when pregnancy does occur in a woman already on tadalafil for PAH, the risk-benefit calculation is complex and requires specialist input.

Data on tadalafil in breast milk are limited. Animal studies suggest low transfer; human data are insufficient for a firm recommendation.

Contraception Checklist for Women on Prolia

• Prolia requires effective contraception during treatment and for five months after the last dose
• Hormonal contraceptives (combined pill, patch, ring, progestin-only methods, hormonal IUD) are not affected pharmacokinetically by denosumab
• If you are also taking tadalafil for PAH, pregnancy itself is a high-risk situation; a long-acting reversible contraceptive (copper IUD or hormonal IUD) is often the most reliable option

Who This Is Right For and Who Should Be Cautious

Life-Stage Framing

Postmenopausal women with osteoporosis and PAH: This is the most common real-world scenario in which Prolia and tadalafil overlap. The combination is generally manageable, with attention to blood pressure, calcium levels, and the rest of your medication list.

Perimenopausal women with POI or secondary osteoporosis: If you are in this group and are considering or already on tadalafil for PAH, confirm that your contraception is reliable and that your prescriber is aware of all your medications.

Women on glucocorticoids who develop secondary osteoporosis: The ACOG Committee Opinion on osteoporosis supports denosumab for glucocorticoid-induced osteoporosis when bisphosphonates are not tolerated. Glucocorticoid use itself can lower blood pressure acutely or chronically, adding another layer to the hemodynamic picture if tadalafil is co-prescribed.

Who Should Be Most Cautious

• Women with known hypocalcemia or severe renal impairment (GFR <30 mL/min) before starting Prolia
• Women who take nitrates in any form (isosorbide mononitrate, nitroglycerin) and are considering tadalafil; this combination is contraindicated regardless of denosumab
• Women on multiple antihypertensives already at or below target blood pressure who are adding tadalafil

Bisphosphonate Alternative if Tadalafil Raises Concern

If a prescriber is hesitant about the broader cardiovascular picture and wants to simplify management, oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) carry their own tolerability issues but have no vasodilatory pharmacodynamic properties and no interaction with tadalafil.

Monitoring Plan When You Take Both

Your prescriber should build in a structured follow-up after starting or continuing either drug.

After Each Prolia Injection

• Serum calcium, magnesium, and phosphate within 2 to 4 weeks, particularly if you have renal impairment or malabsorption
• Blood pressure check, especially in the first month after starting tadalafil or adding a new antihypertensive
• Symptom review for signs of hypocalcemia: muscle cramps, perioral numbness, tetany

Ongoing

• Bone mineral density (DXA scan) every 1 to 2 years while on Prolia
• Dental exam before starting denosumab and at regular intervals; osteonecrosis of the jaw, while rare (estimated 0.04 percent per patient-year in the osteoporosis population), is more likely with invasive dental procedures
• Blood pressure monitoring at home if you take tadalafil plus any antihypertensive

What to Tell Your Doctor

Bring a complete medication list to every appointment, not just prescription drugs. Include:

1. All antihypertensives, especially nitrates and alpha-blockers
2. Antifungal medications (azoles inhibit CYP3A4 and raise tadalafil levels)
3. Seizure medications (carbamazepine, phenytoin reduce tadalafil efficacy)
4. Calcium and vitamin D supplements and dose
5. Any herbal products; St. John's Wort is a CYP3A4 inducer and will lower tadalafil exposure

As WomanRx clinician reviewer Dr. Elena Vasquez notes: "The denosumab-tadalafil pairing itself is not what keeps me up at night. What I always check is whether the woman taking tadalafil for PAH is also on an alpha-blocker for bladder symptoms or a nitrate she was given after a cardiac event. Those are the combinations that can drop blood pressure fast, and Prolia has nothing to do with it."

A Note on Evidence Gaps in Women

Women have been systematically under-represented in cardiovascular and PDE5-inhibitor drug trials. The FREEDOM trial that established denosumab's efficacy enrolled postmenopausal women, so the osteoporosis evidence base is actually more female-specific than most. The tadalafil data are the weak point. Most tadalafil pharmacokinetic studies enrolled men. Dose-finding for PAH included women, but sex-stratified PK analyses are not routinely published. This means the exact degree to which a postmenopausal woman may experience greater vasodilation from tadalafil than a man of the same weight, due to differences in body composition, plasma volume, and vascular reactivity, remains incompletely quantified.

The 2018 ESC/ERS Guidelines for Pulmonary Hypertension acknowledge that women predominate in PAH cohorts yet most data come from mixed-sex trials without sex-specific subgroup analyses. This is an evidence gap your clinician should name plainly, not paper over.

Practical Checklist: Prolia Plus Tadalafil

• Confirm no nitrate use before tadalafil is prescribed
• Check serum calcium before each Prolia injection
• Take at least 1,000 mg calcium and 400 IU vitamin D daily while on Prolia
• Monitor blood pressure at home, especially after adding any new vasodilator
• Tell your dentist you are on denosumab before any extraction or implant procedure
• If you are premenopausal or perimenopausal and on Prolia, use effective contraception and continue for five months after your last injection
• Review the full medication list, including over-the-counter antifungals and herbal products, with your prescriber and pharmacist every six months